Intervention of Shugan Xiaozhi Decoction on Nonalcoholic Fatty Liver Disease via Mediating Gut-Liver Axis

被引:5
|
作者
Yang, Huili [1 ,2 ]
Feng, Lian [1 ,2 ]
Xu, Linyi [1 ,2 ]
Jiang, Dansheng [1 ,2 ]
Zhai, Fenfen [3 ]
Tong, Guangdong [1 ]
Xing, Yufeng [1 ]
机构
[1] Shenzhen Tradit Chinese Med Hosp, Hepatol Dept, Shenzhen 518033, Guangdong, Peoples R China
[2] Guangzhou Univ Chinese Med, Clin Med Coll 4, Shenzhen 518033, Guangdong, Peoples R China
[3] Shenzhen Futian Ctr Chron Dis Control, Shenzhen 518048, Guangdong, Peoples R China
关键词
APOLIPOPROTEIN-B; PPAR-ALPHA; MICROBIOTA; METABOLISM; PROGRESSION; DEFICIENCY; DISORDERS; BACTERIA; RECEPTOR; OBESITY;
D O I
10.1155/2022/4801695
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Nonalcoholic fatty liver disease (NAFLD) is a chronic liver disease with an increasing incidence rate but few therapies. Shugan Xiaozhi decoction (SX) has demonstrated beneficial effects in treating NAFLD with an unclear mechanism. This study was aimed at investigating the therapeutic mechanism of SX on high-fat diet-induced NAFLD rats via the gut-liver axis. Hepatic steatosis and integrity of intestinal mucosa in NAFLD rats were assessed by histopathological staining. The level of lipid and inflammation were estimated by enzyme-linked immunosorbent assay. Western Blotting was used to detect apolipoprotein (apo) B48 expression. 16S rRNA analysis was used to measure the changes of gut microbial composition after SX treatment. The expressions of zona occludens 1 protein (ZO-1), occludin, and secretory immunoglobulin A (sIgA) in the colon were detected by immunostaining to investigate the intestinal barrier function. Our study found that SX reduced hepatic steatosis, the levels of alanine aminotransferase, aspartate aminotransferase, total cholesterol, and triglyceride and apoB48 expression but increased peroxisome proliferator activated receptor alpha (PPAR alpha) level. Moreover, SX altered the diversity of gut microbiota, upregulating the relative abundance of f_Prevotellaceae, while downregulating f_Bacteroidales_ S24-7, f_Lachnospiraceae, f_Ruminococcaceae, f_Erysipelotrichaceae, and f_Desulfovibrionaceae. By increasing the expression of ZO-1 and occludin and decreasing the level of proinflammatory factors, including sIgA, lipopolysaccharide, tumor necrosis factor-alpha, interleukin-1 beta, monocyte chemotactic protein-1, and transforming growth factor-beta 1, SX improved intestinal mucosal integrity and barrier function. Our study illustrated that the gut-liver axis was a potential way for SX to ameliorate NAFLD, that is, by regulating the expression of PPAR alpha, apoB48, and modulating gut microbiota to protect the intestinal barrier function, and thus alleviate lipid deposition and inflammatory response in the liver.
引用
收藏
页数:15
相关论文
共 50 条
  • [21] The Gut-Liver Axis in Pediatric Liver Health and Disease
    Rager, Stephanie L.
    Zeng, Melody Y.
    MICROORGANISMS, 2023, 11 (03)
  • [22] Involvement of the liver-gut peripheral neural axis in nonalcoholic fatty liver disease pathologies via hepatic HTR2A
    Owaki, Takashi
    Kamimura, Kenya
    Ko, Masayoshi
    Nagayama, Itsuo
    Nagoya, Takuro
    Shibata, Osamu
    Oda, Chiyumi
    Morita, Shinichi
    Kimura, Atsushi
    Sato, Takeki
    Setsu, Toru
    Sakamaki, Akira
    Kamimura, Hiroteru
    Yokoo, Takeshi
    Terai, Shuji
    DISEASE MODELS & MECHANISMS, 2022, 15 (07)
  • [23] Assessment of Nonalcoholic Fatty Liver Disease Symptoms and Gut-Liver Axis Status in Zebrafish after Exposure to Polystyrene Microplastics and Oxytetracycline, Alone and in Combination
    Zhou, Weishang
    Shi, Wei
    Du, Xueying
    Han, Yu
    Tang, Yu
    Ri, Sanghyok
    Ju, Kwangjin
    Kim, Tongchol
    Huang, Lin
    Zhang, Weixia
    Yu, Yihan
    Tian, Dandan
    Yu, Yingying
    Chen, Liangbiao
    Wu, Zhichao
    Liu, Guangxu
    ENVIRONMENTAL HEALTH PERSPECTIVES, 2023, 131 (04)
  • [24] The Role of the Gut-Liver Axis in Metabolic Dysfunction-Associated Fatty Liver Disease
    Martin-Mateos, Rosa
    Albillos, Agustin
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [25] Luteolin alleviates non-alcoholic fatty liver disease in rats via restoration of intestinal mucosal barrier damage and microbiota imbalance involving in gut-liver axis
    Liu, Xia
    Sun, Runzhou
    Li, Zhaozhen
    Xiao, Ruixin
    Lv, Pengfei
    Sun, Xiangrong
    Olson, Mark A.
    Gong, Yanling
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2021, 711
  • [26] Importance of the gut microbiota in the gut-liver axis in normal and liver disease
    Kotlyarov, Stanislav
    WORLD JOURNAL OF HEPATOLOGY, 2024, 16 (06)
  • [27] Sulforaphane Ameliorates Nonalcoholic Fatty Liver Disease Induced by High-Fat and High-Fructose Diet via LPS/TLR4 in the Gut-Liver Axis
    Xu, Ye
    Huang, Xianghui
    Huangfu, Bingxin
    Hu, Yanzhou
    Xu, Jia
    Gao, Ruxin
    Huang, Kunlun
    He, Xiaoyun
    NUTRIENTS, 2023, 15 (03)
  • [28] Gut microbiota and nonalcoholic fatty liver disease
    Machado, Mariana V.
    Cortez-Pinto, Helena
    ANNALS OF HEPATOLOGY, 2012, 11 (04) : 440 - 449
  • [29] Liver-spleen axis in nonalcoholic fatty liver disease
    Tarantino, Giovanni
    Citro, Vincenzo
    Balsano, Clara
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2021, 15 (07) : 759 - 769
  • [30] Nonalcoholic Fatty Liver Disease (NAFLD) as Model of Gut-Liver Axis Interaction: From Pathophysiology to Potential Target of Treatment for Personalized Therapy
    Fianchi, Francesca
    Liguori, Antonio
    Gasbarrini, Antonio
    Grieco, Antonio
    Miele, Luca
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (12)